Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Control Release ; 369: 734-745, 2024 May.
Article in English | MEDLINE | ID: mdl-38604385

ABSTRACT

Despite research efforts being made towards preserving (or even regenerating) heart tissue after an ischemic event, there is a lack of resources in current clinical treatment modalities for patients with acute myocardial infarction that specifically address cardiac tissue impairment. Modified messenger RNA (modRNA) presents compelling properties that could allow new therapeutic strategies to tackle the underlying molecular pathways that ultimately lead to development of chronic heart failure. However, clinical application of modRNA for the heart is challenged by the lack of effective and safe delivery systems. Lipid nanoparticles (LNPs) represent a well characterized class of RNA delivery systems, which were recently approved for clinical usage in mRNA-based COVID-19 vaccines. In this study, we evaluated the potential of LNPs for cardiac delivery of modRNA. We tested how variations in C12-200 modRNA-LNP composition affect transfection levels and biodistribution after intramyocardial administration in both healthy and myocardial-infarcted mice, and determined the targeted cardiac cell types. Our data revealed that LNP-mediated modRNA delivery outperforms the current state of the art (modRNA in citrate buffer) upon intramyocardial administration in mice, with only minor differences among the formulations tested. Furthermore, we determined both in vitro and in vivo that the cardiac cells targeted by modRNA-LNPs include fibroblasts, endothelial cells and epicardial cells, suggesting that these cell types could represent targets for therapeutic interference with these LNP formulations. These outcomes may serve as a starting point for LNP development specifically for therapeutic mRNA cardiac delivery applications.


Subject(s)
Mice, Inbred C57BL , Myocardial Infarction , Myocardium , Nanoparticles , RNA, Messenger , Animals , RNA, Messenger/administration & dosage , Tissue Distribution , Myocardial Infarction/therapy , Myocardium/metabolism , Lipids/chemistry , Mice , Humans , Male , Gene Transfer Techniques , Transfection/methods , Liposomes
2.
Auton Neurosci ; 221: 102580, 2019 11.
Article in English | MEDLINE | ID: mdl-31491700

ABSTRACT

OBJECTIVES: In cardiac ischemia, acute inflammatory responses further increase the detrimental effect on myocardial tissue. Since vagus nerve stimulation (VS) attenuates inflammatory responsiveness this study examines the effect of VS on myocardial damage development in a cardiac ischemia-reperfusion (IR) mouse model. METHODS: 54 male C57Bl/6j mice were subjected to an IR procedure with or without prior VS. The effects on inflammatory responsiveness, infarct size, cardiac function, neutrophils, lymphocytes and vascular endothelial growth factor (VEGF) in the infarcted myocardium were measured at 48 h after intervention. Group results were compared with unpaired Mann-Whitney or Kruskall-Wallis test. RESULTS: A significant decrease in inflammatory responsiveness was not verified by decreased TNFα levels in blood from VS and IR treated mice. The percentage infarct size over area at risk was smaller in the group with VS + IR compared with IR (22.4 ±â€¯10.2% vs 37.6 ±â€¯9.0%, p = 0.003). The degree of the reduction in cardiac function was not different between the IR groups with or without VS and no group differences were found in amounts of neutrophils, CD3+ lymphocytes and VEGF in the reperfused mouse heart. CONCLUSION: The present study does not provide clear evidence of a reducing role for VS on cardiac function loss. This could mean that VS has a less inhibiting effect on myocardial inflammation than may be expected from the literature.


Subject(s)
Myocardial Reperfusion Injury/therapy , Vagus Nerve Stimulation , Animals , Inflammation , Lymphocyte Subsets/immunology , Male , Mice , Mice, Inbred C57BL , Models, Animal , Myocardial Reperfusion Injury/immunology , Myocardial Reperfusion Injury/pathology , Myocardial Reperfusion Injury/physiopathology , Myocardium/chemistry , Myocardium/pathology , Neutrophils/immunology , Stroke Volume , Tumor Necrosis Factor-alpha/blood , Vascular Endothelial Growth Factor A/analysis
3.
Gene Ther ; 21(2): 205-11, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24385145

ABSTRACT

RNA interference (RNAi) is a powerful strategy for unraveling gene function and for drug target validation, but exogenous expression of short hairpin RNAs (shRNAs) has been associated with severe side effects. These may be caused by saturation of the microRNA pathway. This study shows degenerative changes in cell morphology and intrusion of blood vessels after transduction of the ventromedial hypothalamus (VMH) of rats with a shRNA expressing adeno-associated viral (AAV) vector. To investigate whether saturation of the microRNA pathway has a role in the observed side effects, expression of neuronal microRNA miR-124 was used as a marker. Neurons transduced with the AAV vector carrying the shRNA displayed a decrease in miR-124 expression. The decreased expression was unrelated to shRNA sequence or target and observed as early as 1 week after injection. In conclusion, this study shows that the tissue response after AAV-directed expression of a shRNA to the VMH is likely to be caused by shRNA-induced saturation of the microRNA pathway. We recommend controlling for miR-124 expression when using RNAi as a tool for studying (loss of) gene function in the brain as phenotypic effects caused by saturation of the RNAi pathway might mask true effects of specific downregulation of the shRNA target.


Subject(s)
Genetic Vectors/adverse effects , MicroRNAs/genetics , Neurons/metabolism , RNA, Small Interfering/pharmacology , Signal Transduction/drug effects , Animals , Dependovirus/genetics , Gene Expression Regulation , Genetic Vectors/administration & dosage , MicroRNAs/toxicity , Organ Specificity , RNA, Small Interfering/genetics , Rats , Rats, Wistar , Ventromedial Hypothalamic Nucleus/metabolism
4.
Int J Obes (Lond) ; 38(5): 643-9, 2014 May.
Article in English | MEDLINE | ID: mdl-23979221

ABSTRACT

OBJECTIVES: Rats subjected to a free-choice high-fat high-sugar (fcHFHS) diet persistently overeat, exhibit increased food-motivated behavior and become overtly obese. Conversely, several studies using a non-choice (nc) high-energy diet showed only an initial increase in food intake with unaltered or reduced food-motivated behavior. This raises the question of the importance of choice in the persistence of hyperphagia in rats on a fcHFHS diet. SUBJECTS: Meal patterns, food intake and body weight gain were studied in male Wistar rats on free-choice diets with fat and/or sugar and in rats on nc diets with fat and sugar (custom made with ingredients similar to the fcHFHS diet). RESULTS: Rats on a ncHFHS diet initially overconsumed, but reduced intake thereafter, whereas rats on a fcHFHS diet remained hyperphagic. Because half of the sugar intake in the fcHFHS group occurred during the inactive period, we next determined whether sugar intake during the light phase was a necessary requirement for hyperphagia, by restricting access to liquid sugar to either the light or dark period with unlimited access to fat and chow. Results showed that hyperphagia occurred irrespective of the timing of sugar intake. Meal pattern analysis revealed consumption of larger but fewer meals in the ncHFHS group, as well as the fcHF group. Interestingly, meal number was increased in all rats drinking liquid sugar (whether on a fcHFHS or a fcHS diet), whereas a compensatory decrease in meal size was only observed in the fcHS group, but not the fcHFHS group. CONCLUSION: We hereby show the importance of choice in the observation of fcHFHS diet-induced hyperphagia, which results in increases in meal number due to sugar drinking without any compensatory decrease in meal size. We thus provide a novel dietary model in rats that mimics important features of human overconsumption that have been ignored in rodent models of obesity.


Subject(s)
Hyperphagia/pathology , Obesity/pathology , Snacks , Weight Gain , Animals , Body Weight , Choice Behavior , Dietary Fats , Dietary Sucrose , Disease Models, Animal , Eating , Energy Intake , Feeding Behavior , Hyperphagia/blood , Male , Obesity/blood , Rats , Rats, Wistar
5.
Int J Obes (Lond) ; 36(2): 254-61, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21556042

ABSTRACT

OBJECTIVE: Significant weight gain is a problematic side effect of treatment with the antipsychotic drug olanzapine (OLA). Previous studies in rats suggest that one of the contributing factors is an impairment in satiation that results in increased food intake. However, the mechanisms underlying this impairment in satiation remain largely unclear. METHODS AND RESULTS: In this study, we determined the effect of OLA on levels of leptin, insulin, ghrelin, cholecystokinin (CCK), glucagon-like peptide-1, peptide YY and amylin in male rats that had received a fixed amount of food. OLA did not affect the secretion of any of these hormones, except for ghrelin levels, which were increased compared with controls. Furthermore, when ghrelin levels were determined in rats just before they received their meal, OLA caused a significant increase in ghrelin levels compared with controls, whereas OLA failed to affect baseline ghrelin levels. Next, we investigated the effect of OLA on the efficacy of CCK to reduce meal size. With coadministration, OLA pretreatment counteracted the reduction in meal size by CCK, although there was no significant interaction between the treatments. Finally, telemetry measurements revealed that acute OLA treatment causes a temporary decrease in both locomotor activity and body core temperature. CONCLUSION: Taken together, this study shows that acute injection of OLA selectively increases meal-related ghrelin secretion and this may partially underlie the impairment in satiation by OLA.


Subject(s)
Antipsychotic Agents/pharmacology , Benzodiazepines/pharmacology , Body Temperature/drug effects , Cholecystokinin/drug effects , Ghrelin/drug effects , Motor Activity/drug effects , Peptide YY/drug effects , Analysis of Variance , Animals , Cholecystokinin/metabolism , Eating , Ghrelin/metabolism , Glucagon-Like Peptide 1/drug effects , Glucagon-Like Peptide 1/metabolism , Islet Amyloid Polypeptide/drug effects , Islet Amyloid Polypeptide/metabolism , Male , Olanzapine , Peptide YY/metabolism , Rats , Rats, Wistar , Satiation/drug effects
6.
Int J Obes (Lond) ; 35(5): 629-41, 2011 May.
Article in English | MEDLINE | ID: mdl-20733584

ABSTRACT

OBJECTIVE: Reduction of melanocortin signaling in the brain results in obesity. However, where in the brain reduced melanocortin signaling mediates this effect is poorly understood. DESIGN: We determined the effects of long-term inhibition of melanocortin receptor activity in specific brain regions of the rat brain. Melanocortin signaling was inhibited by injection of a recombinant adeno-associated viral (rAAV) vector that overexpressed Agouti-related peptide (AgRP) into the paraventricular nucleus (PVN), the ventromedial hypothalamus (VMH), the lateral hypothalamus (LH) or the accumbens shell (Acc). RESULTS: Overexpression of AgRP in the rat PVN, VMH or LH increased bodyweight, the percentage of white adipose tissue, plasma leptin and insulin concentrations and food intake. Food intake was mainly increased because of an increase in meal size in the light and dark phases, after overexpression of AgRP in the PVN, LH or VMH. Overexpression of AgRP in the PVN or VMH reduced average body core temperature in the dark on day 40 post injection, whereas AgRP overexpression in the LH did not affect temperature. In addition, overexpression of AgRP in the PVN, LH or VMH did not significantly alter mRNA expression of AgRP, neuropeptide Y (NPY), pro-opiomelanocortin (POMC) or suppressor of cytokine signaling 3 (SOCS3) in the arcuate. Overexpression of AgRP in the Acc did not have any effect on the measured parameters. CONCLUSIONS: Reduction of melanocortin signaling in several hypothalamic regions increased meal size. However, there were brain area-specific effects on other parameters such as core temperature and plasma leptin concentrations. In a previous study, where NPY was overexpressed with an rAAV vector in the PVN and LH, meal frequency and meal size were increased respectively, whereas locomotor activity was reduced by NPY overexpression at both nuclei. Taken together, AgRP and NPY have complementary roles in energy balance.


Subject(s)
Agouti-Related Protein/metabolism , Body Weight/physiology , Energy Metabolism/physiology , Hypothalamus/metabolism , Obesity/metabolism , Receptors, Melanocortin/physiology , Animals , Cell Line , Eating/physiology , Hypothalamic Area, Lateral/metabolism , Hypothalamus/physiology , Male , Midline Thalamic Nuclei/metabolism , Nucleus Accumbens/metabolism , Obesity/physiopathology , Rats , Rats, Wistar , Receptors, Melanocortin/antagonists & inhibitors , Ventromedial Hypothalamic Nucleus/metabolism
7.
J Mol Endocrinol ; 45(5): 341-53, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20819948

ABSTRACT

An increase in brain suppressor of cytokine signaling 3 (SOCS3) has been implicated in the development of both leptin and insulin resistance. Socs3 mRNA is localized throughout the brain, and it remains unclear which brain areas are involved in the effect of SOCS3 levels on energy balance. We investigated the role of SOCS3 expressed in the mediobasal hypothalamus (MBH) in the development of diet-induced obesity in adult rats. Socs3 mRNA was down-regulated by local injection of adeno-associated viral vectors expressing a short hairpin directed against Socs3, after which we determined the response to high-fat high-sucrose choice diet. In contrast to neuronal Socs3 knockout mice, rats with SOCS3 knockdown limited to the MBH showed increased body weight gain, larger amounts of white adipose tissue, and higher leptin concentrations at the end of the experiment. These effects were partly due to the decrease in locomotor activity, as 24 h food intake was comparable with controls. In addition, rats with Socs3 knockdown in the MBH showed alterations in their meal patterns: average meal size in the light period was increased and was accompanied by a compensatory decrease in meal frequency in the dark phase. In addition, neuropeptide Y (Npy) mRNA levels were significantly increased in the arcuate nucleus of Socs3 knockdown rats. Since leptin is known to stimulate Npy transcription in the absence of Socs3, these data suggest that knockdown of Socs3 mRNA limited to the MBH increases Npy mRNA levels, which subsequently decreases locomotor activity and alters feeding patterns.


Subject(s)
Energy Metabolism , Feeding Behavior , Hypothalamus/metabolism , Obesity/metabolism , Suppressor of Cytokine Signaling Proteins/genetics , Suppressor of Cytokine Signaling Proteins/physiology , Animals , Body Composition , Body Weight/physiology , Brain/metabolism , Down-Regulation , Gene Knockdown Techniques , HEK293 Cells , Humans , Insulin/metabolism , Leptin/metabolism , Male , Neuropeptide Y/genetics , Neuropeptide Y/metabolism , RNA, Messenger/genetics , RNA, Small Interfering , Rats , Rats, Wistar , Signal Transduction , Weight Gain
SELECTION OF CITATIONS
SEARCH DETAIL
...